Cancer Family
Lung Neoplasm
CI-CAN-00000221Explore in graph →
Non-malignant2,726 active trials51 approved drugs619 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000221Explore in graph →
Clinical trials
11,603 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06573073 | Evaluation of Clinical Performance and IVD Test of LifeOS Digital PCR Liquid Biopsy Kits for EGFR T790M Mutation | recruiting | — | 300 | LifeOS Genomics CorporationINDUSTRY | 1 | Nov 18, 2024 | clinicaltrials |
| NCT04787042 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | recruiting | Phase 1 / Phase 2 | 316 | Simcha IL-18, Inc.INDUSTRY | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06690385 | DEPRECAP: Lung Cancer Screening Programme by LDCT for Patients With COPD or Emphysema.(DEPRECAP) | recruiting | — | 1,998 | Instituto de Investigación Sanitaria de la Fundación Jiménez DíazOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT05671887 | DREAM: Double Lung Transplant REgistry Aimed for Lung-limited Malignancies(DREAM) | recruiting | — | 125 | Northwestern UniversityOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT06426628 | Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier(NIGHTINGALE) | recruiting | — | 2,400 | Veracyte, Inc.INDUSTRY | 2 | Nov 13, 2024 | clinicaltrials |
| NCT06589778 | A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 124 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06604689 | AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases | recruiting | — | 800 | Fudan UniversityOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06388031 | ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI | recruiting | Phase 2 | 27 | Peking Union Medical College HospitalOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT06674343 | Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations | recruiting | Phase 3 | 144 | Peking Union Medical College HospitalOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT05435248 | Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC) | recruiting | Phase 1 / Phase 2 | 354 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 4, 2024 | clinicaltrials |
| NCT06667154 | Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy | recruiting | Phase 2 | 33 | Aline Fusco Fares, MDOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT05468242 | Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy | recruiting | Phase 2 | 116 | Sun Yat-sen UniversityOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT05403554 | A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers | recruiting | Phase 1 | 70 | Light Chain Bioscience - Novimmune SAINDUSTRY | 2 | Oct 29, 2024 | clinicaltrials |
| NCT05772455 | A Study of XZB-0004 in Patients With Solid Tumors | recruiting | Phase 1 | 128 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 28, 2024 | clinicaltrials |
| NCT06084806 | Test-retest Evaluation of [18F]F-AraG PET | recruiting | Phase 2 | 10 | CellSight Technologies, Inc.INDUSTRY | 1 | Oct 24, 2024 | clinicaltrials |
| NCT06107374 | Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG | recruiting | Phase 2 | 20 | CellSight Technologies, Inc.INDUSTRY | 1 | Oct 24, 2024 | clinicaltrials |
| NCT04322890 | Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation(PIKACHU) | recruiting | Phase 2 | 6,000 | Hunan Province Tumor HospitalOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT04335292 | Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge(OCELOT) | recruiting | Phase 2 | 200 | Mark VincentOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT06653478 | Development and Demonstration of Intelligent Assessment Based on Multi-modal Information Fusion for Tumor Risk and Diagnosis and Treatment | recruiting | — | 3,000 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT05925764 | WSI Based DL for Diagnosing the IASLC Grading System of Lung Adenocarcinoma | recruiting | — | 200 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT05501665 | Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer | recruiting | Phase 1 / Phase 2 | 25 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT04605146 | Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy(MONITOR) | recruiting | N/A | 100 | Hospices Civils de LyonOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06498479 | ARTEMIS-008:HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer | recruiting | Phase 3 | 460 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Oct 16, 2024 | clinicaltrials |
| NCT05487391 | A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection. | recruiting | Phase 3 | 632 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05902559 | Assessment of Novel Biomarkers in Participants Undergoing Targeted Lung Health Checks(ALPINE) | recruiting | — | 10,000 | University College, LondonOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06538012 | TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer(BAH2472) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06607770 | Safety and Efficacy of Cryoablation With Karelizumab and Apatinib for Multiple Lung Cancers | recruiting | Phase 1 / Phase 2 | 20 | Zhou ChengzhiOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06634966 | Segmentectomy for Solid-dominant Lung Cancer | recruiting | Phase 3 | 277 | Fudan UniversityOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06632886 | AI-Assisted Non-Contrast CT for Multi-Cancer Screening | recruiting | N/A | 1,000,000 | Guo ShiWeiOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT05878964 | Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.(SkinHealth) | recruiting | — | 420 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Oct 4, 2024 | clinicaltrials |
| NCT06628102 | Improving Detection of Early Lung Cancer in a Diverse Population (IDEAL) Study(IDEAL) | recruiting | N/A | 3,600 | British Columbia Cancer AgencyOTHER | 1 | Oct 4, 2024 | clinicaltrials |
| NCT06626178 | Development of an Artificial Intelligence Model for the Identification and Prevention of Smoking-related Diseases.(ARIA) | recruiting | N/A | 2,840 | Scientific Institute San RaffaeleOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT06623487 | The Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer | recruiting | — | 30 | Ruijin HospitalOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT06247163 | PET-guided Radiotherapy for Patients With Small Cell Lung Cancer.(PET-ART) | recruiting | — | 30 | University Hospital, EssenOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06607796 | Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy | recruiting | Phase 3 | 180 | Zhou ChengzhiOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT05557552 | Sequential Chemo-immunotherapy Plus Thoracic Radiotherapy for Elderly And/or Frail Stage III Non-small-cell Lung Cancer | recruiting | N/A | 56 | Ruijin HospitalOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT05974475 | MONDRIAN: Multi-omics Integrative Modelling for Stereotactic Body Radiotherapy in Early-stage Non-small Cell Lung Cancer(MONDRIAN) | recruiting | — | 270 | European Institute of OncologyOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT06608160 | 68Ga-grazytracer PET Assists in Diagnosing Pseudoprogression Following Immunotherapy in Lung Cancer. | recruiting | — | 30 | Ruijin HospitalOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT05014464 | ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma(ATPase) | recruiting | Phase 2 | 90 | Hunan Province Tumor HospitalOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT05991193 | A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer | recruiting | — | 100 | Hunan Province Tumor HospitalOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT06355609 | Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW(WUKONG-32-RW) | recruiting | Phase 2 | 100 | Hunan Province Tumor HospitalOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT04324125 | Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC | recruiting | — | 70 | Hunan Province Tumor HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04324151 | Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC | recruiting | — | 70 | Hunan Province Tumor HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04777175 | A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer | recruiting | — | 186 | Yongchang ZhangOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04951947 | JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer | recruiting | Phase 2 | 30 | Hunan Province Tumor HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05295212 | Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB | recruiting | Phase 2 | 120 | Hunan Province Tumor HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05379803 | High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases | recruiting | Phase 2 | 40 | Hunan Province Tumor HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05766800 | Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer | recruiting | Phase 2 | 100 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05830812 | Improving the Intraoperative Diagnosis Accuracy of Invasiveness for Small-sized Lung Adenocarcinoma | recruiting | — | 3,000 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06105177 | Implementation of Up-front ctDNA Into Lung Cancer Care and Development of Liquid Biopsy-based Decision Support Models - LM² Study(LM2) | recruiting | — | 800 | Catharina Ziekenhuis EindhovenOTHER | 1 | Sep 19, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Nov 18, 2024source: clinicaltrials